SN vs NVCR vs NKTR vs HELE

For growth investors, SharkNinja, Inc.

(SN) is the stronger pick with 15. 7% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). SharkNinja, Inc. (SN) offers the better valuation at 22. 9x trailing P/E (18. 7x forward), making it the more compelling value choice. Analysts rate SharkNinja, Inc. (SN) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Helen of Troy Limited is actually cheaper at 7.

5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, SharkNinja, Inc.

(SN) delivered a total return of +169. 9%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: SN returned +169. 9% versus HELE's -74. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Helen of Troy Limited (HELE) is the lower-risk stock at 1.

65β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 33% more volatile than HELE relative to the S&P 500. On balance sheet safety, Helen of Troy Limited (HELE) carries a lower debt/equity ratio of 10% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), SharkNinja, Inc.

(SN) is pulling ahead at 15. 7% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: SharkNinja, Inc. grew EPS 58. 8% year-over-year, compared to -827. 7% for Helen of Troy Limited. Over a 3-year CAGR, SN leads at 19. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

SharkNinja, Inc.

(SN) is the more profitable company, earning 11. 0% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 11. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SN leads at 14. 4% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Helen of Troy Limited (HELE) trades at 7.

5x forward P/E versus 18. 7x for SharkNinja, Inc. — 11. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Helen of Troy Limited (HELE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.

NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HELE: -74. 4%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SN (Consumer Cyclical) and NVCR (Healthcare) and NKTR (Healthcare) and HELE (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SN is a mid-cap high-growth stock; NVCR is a small-cap quality compounder stock; NKTR is a small-cap quality compounder stock; HELE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.